Select your language close

Dr Philip Ancliff

Consultant in Paediatric Haematology
Dr. Philip Ancliff

Overview

Dr Philip Ancliff is an experienced paediatric haematologist (appointed to GOSH in 2003) with extensive practice in all areas of malignant haematology.  His research covers the spectrum from the basic science of the pathogenesis of leukaemia, through optimising mainstream treatment to novel immunotherapeutic approaches.  He also has expertise in severe congenital neutropenia and bone marrow failure disorders.  Dr Ancliff chairs the UK National Cancer Research Institute’s Childhood Leukaemia study group.

Credentials

  • Paediatric leukaemias and related disorders 

  • Severe congenital neutropenia 

  • Bone marrow failure syndromes

  • 1987 - 1992University of Cambridge and Addenbrookes’s Hospital Clinical School 
  • 1993 – 1994General medical training, Leeds General Infirmary 
  • 1995 – 1999Specialist Haematology Training, UCL Hospitals and GOSH 
  • 2000 – 2003PhD, UCL. “Pathogenesis of Severe Congenital Neutropenia”
  • MA 
  • MRCP 
  • MRCPath 
  • FRCP
  • FRCPath  
  • Long-standing member of NCRI Childhood Leukaemia sub group both myeloid and lymphoid taskforces and predecessors since appointment as consultant, currently Chair 

  • National Coordinator for Interfant 06 – International protocol for the treatment of Acute Lymphoblastic Leukaemia in Infants 

  • Associate Coordinator UKALL R3 trial - International protocol for relapsed Acute Lymphoblastic Leukaemia 

  • Co-investigator MyeChild 01 – International Phase III Trial for children with AML with embedded dose-finding study for Gemtuzumab Ozogamicin  

  • Member of GECIP for Stem cell and myeloid disorders

  • Immunophenotypic characterisation of normal bone marrow in infants and children, 2017 

  • Molecular genetic and cytogenetic characterisation of genetically unclassified subtypes of childhood precursor B-lineage Acute Lymphoblastic Leukaemia, 2016 

  • International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy, 2016 

News & Publications

MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia.  Germeshausen M, Ancliff P, Estrada J, Metzler M, Ponstingl E, Rütschle H, Schwabe D, Scott RH, Unal S, Wawer A, Zeller B, Ballmaier M. 

Blood Adv. 2018 Mar 27;2(6):586-596. 

Targeting acute myeloid leukemia by drug-induced c-MYB degradation.  Walf-Vorderwülbecke V, Pearce K, Brooks T, Hubank M, van den Heuvel-Eibrink MM, Zwaan CM, Adams S, Edwards D, Bartram J, Samarasinghe S, Ancliff P, Khwaja A, Goulden N, Williams G, de Boer J, Williams O. 

Leukemia. 2018 Apr;32(4):882-889 

Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies. 

Cardoso SR, Ellison ACM, Walne AJ, Cassiman D, Raghavan M, Kishore B, Ancliff P, Rodríguez-Vigil C, Dobbels B, Rio-Machin A, Al Seraihi AFH, Pontikos N, Tummala H, Vulliamy T, Dokal I. 

Haematologica. 2017 Aug;102(8):e293-e296 

Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation.  Fioredda F, Iacobelli S, van Biezen A, Gaspar B, Ancliff P, Donadieu J, Aljurf M, Peters C, Calvillo M, Matthes-Martin S, Morreale G, van 't Veer-Tazelaar N, de Wreede L, Al Seraihy A, Yesilipek A, Fischer A, Bierings M, Ozturk G, Smith O, Veys P, Ljungman P, Peffault de Latour R, Sánchez de Toledo Codina J, Or R, Ganser A, Afanasyev B, Wynn R, Kalwak K, Marsh J, Dufour C 

Blood. 2015 Oct 15;126(16):1885-92;  

Disease evolution and outcomes in familial AML with germline CEBPA mutations.  Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. 

Blood. 2015 Sep 3;126(10):1214-23 

Congenital acute megakaryoblastic leukemia. 

Bain BJ, Chakravorty S, Ancliff P. 

Am J Hematol. 2015 Oct;90(10):963.  

PAX5 alterations in genetically unclassified childhood Precursor B-cell acute lymphoblastic leukaemia. 

Stasevich I, Inglott S, Austin N, Chatters S, Chalker J, Addy D, Dryden C, Ancliff P, Ford A, Williams O, Kempski H. 

Br J Haematol. 2015 Jun 26.  

Nutritional status in children with Shwachman-diamond syndrome. 

Pichler J, Meyer R, Köglmeier J, Ancliff P, Shah N. 

Pancreas. 2015 May;44(4):590-5.  

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.  Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V.  

PLoS One. 2014 Oct 3;9(10) 

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. 

Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC, Gale RE. 

Br J Haematol. 2013 Jun;161(5):701-5. 

Squamous cell carcinoma in a child with Clericuzio-type poikiloderma with neutropenia.  Rodgers W, Ancliff P, Ponting CP, Sanchez-Pulido L, Burns S, Hayman M, Kimonis V, Sebire N, Bulstrode N, Harper JI. 

Br J Dermatol. 2013 Mar;168(3):665-7.  

Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.  Temming P, Qureshi A, Hardt J, Leiper AD, Levitt G, Ancliff PJ, Webb DK. 

Pediatr Blood Cancer. 2011 Apr;56(4):625-30.  

Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Bond J, Gale DP, Connor T, Adams S, de Boer J, Gascoyne DM, Williams O, Maxwell PH, Ancliff PJ. 

Blood. 2011 Mar 31;117(13):3699-701.  

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V.   

Lancet. 2010 Dec 11;376(9757):2009-17.  

Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia.  Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M, Gratias EJ, van Wering ER, Cazzaniga G, Harrison CJ, Hain R, Ancliff P, Ford AM, Kearney L, Greaves M. 

Blood. 2010 Apr 29;115(17):3553-8.  

Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindreds. 

Smith BN, Ancliff PJ, Pizzey A, Khwaja A, Linch DC, Gale RE. 

Br J Haematol. 2009 Mar;144(5):762-70.  

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.  Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ 

J Clin Invest. 2008 Sep;118(9):3143-50 

Initiating and tumor-propagating cells in TEL-AML1-associated childhood leukemia.  Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, Tsuzuki S, Greaves M, Enver T 

Science 2008 Jan 18;319(5861):336-9 

Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. Moulding DA, Blundell MP, Spiller DG, White MR, Cory GO, Calle Y, Kempski H, Sinclair J, Ancliff PJ, Kinnon C, Jones GE, Thrasher AJ 

J Exp Med. 2007 Sep 3;204(9):2213-24 

Mutations in the SBDS gene in acquired aplastic anemia. 

Calado RT, Graf SA, Wilkerson KL, Kajigaya S, Ancliff PJ, Dror Y, Chanock SJ, Lansdorp PM, Young NS 

Blood. 2007 Aug 15;110(4):1141-6 

The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. 

Menne TF, Goyenechea B, Sánchez-Puig N, Wong CC, Tonkin LM, Ancliff PJ, Brost RL, Costanzo M, Boone C, Warren AJ. 

Nat Genet. 2007 Apr;39(4):486-95 

Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. 

Ancliff PJ, Blundell MP, Cory GO, Calle Y, Worth A, Kempski H, Burns S, Jones GE, Sinclair J, Kinnon C, Hann IM, Gale RE, Linch DC, Thrasher AJ. 

Blood. 2006 Oct 1;108(7):2182-9 

Congenital neutropenia.  

Ancliff PJ. 

Blood Reviews. 2003 Dec;17(4):209-16 

Neutrophil elastase mutations in congenital neutropenia – genetics and potential mechanisms. 

Ancliff PJ, Gale RE, Linch DC 

Hematology. 2003 Jun; 8(3): 165-71 

Long-Term Follow-Up of G-CSF Receptor Mutations in Patients with Severe Congenital Neutropenia: Implications for Leukaemogenesis and Therapy. 

Ancliff PJ, Gale RE, Liesner R, Hann I & Linch DC 

British Journal of Haematology 2003, 120(4): 685-90 

Paternal Mosaicism Proves the Pathogenic Nature of Mutations in Neutrophil Elastase in Severe Congenital Neutropenia. 

Ancliff PJ, Gale RE, Liesner R, Hann IM, Strobel S & Linch DC 

Blood 2002; 100(2): 707-9 

Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease.  

Ancliff PJ, Gale RE, Liesner R, Hann IM & Linch DC 

Blood 2001 Nov 1; 98(9): 2645-50

Refer your child to Dr Philip Ancliff

Use the form below to refer your child for treatment. A member of our team will be in touch within 2 working days.

Your Details
Relationship to Patient:
Preferred Language:
Patient Details
What is the purpose of your referral?
This is the end of the basic form. Please note, in order to progress with a referral we require a medical report for the patient, therefore if you have this information available now, please click the 'provide more info' button. Alternatively press submit and one of our team will be in touch.
Doctor Details
Any other Doctors involved in Patients care
Funding Details
Who is paying for your treatment?
Medical Records

Mandatory fields

Dr Philip Ancliff Details

You can contact Dr Philip Ancliff through Great Ormond Street Hospital below.

Share Dr Philip Ancliff profile with someone:

Browse A-Z